JP7847433B2 - Egfr抗原結合断片およびそれを含む組成物 - Google Patents

Egfr抗原結合断片およびそれを含む組成物

Info

Publication number
JP7847433B2
JP7847433B2 JP2021576274A JP2021576274A JP7847433B2 JP 7847433 B2 JP7847433 B2 JP 7847433B2 JP 2021576274 A JP2021576274 A JP 2021576274A JP 2021576274 A JP2021576274 A JP 2021576274A JP 7847433 B2 JP7847433 B2 JP 7847433B2
Authority
JP
Japan
Prior art keywords
amino acid
cancer
seq
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538222A (ja
JP2022538222A5 (cg-RX-API-DMAC7.html
Inventor
ヴォルカー シュレンベルガー
ダラ マッキャン
ジェイムズ マクローリー
フィリップ クーン
アンドレ フレンツェル
Original Assignee
アムニクス ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムニクス ファーマシューティカルズ, インコーポレイテッド filed Critical アムニクス ファーマシューティカルズ, インコーポレイテッド
Publication of JP2022538222A publication Critical patent/JP2022538222A/ja
Publication of JP2022538222A5 publication Critical patent/JP2022538222A5/ja
Priority to JP2025138827A priority Critical patent/JP2026000901A/ja
Application granted granted Critical
Publication of JP7847433B2 publication Critical patent/JP7847433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021576274A 2019-06-26 2020-06-25 Egfr抗原結合断片およびそれを含む組成物 Active JP7847433B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025138827A JP2026000901A (ja) 2019-06-26 2025-08-22 Egfr抗原結合断片およびそれを含む組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962866749P 2019-06-26 2019-06-26
US62/866,749 2019-06-26
US202063043486P 2020-06-24 2020-06-24
US63/043,486 2020-06-24
PCT/US2020/039682 WO2020264208A1 (en) 2019-06-26 2020-06-25 Egfr antigen binding fragments and compositions comprising same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025138827A Division JP2026000901A (ja) 2019-06-26 2025-08-22 Egfr抗原結合断片およびそれを含む組成物

Publications (3)

Publication Number Publication Date
JP2022538222A JP2022538222A (ja) 2022-09-01
JP2022538222A5 JP2022538222A5 (cg-RX-API-DMAC7.html) 2023-07-04
JP7847433B2 true JP7847433B2 (ja) 2026-04-17

Family

ID=74060335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576274A Active JP7847433B2 (ja) 2019-06-26 2020-06-25 Egfr抗原結合断片およびそれを含む組成物
JP2025138827A Pending JP2026000901A (ja) 2019-06-26 2025-08-22 Egfr抗原結合断片およびそれを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025138827A Pending JP2026000901A (ja) 2019-06-26 2025-08-22 Egfr抗原結合断片およびそれを含む組成物

Country Status (12)

Country Link
US (1) US20230312729A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990499A4 (cg-RX-API-DMAC7.html)
JP (2) JP7847433B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038356A (cg-RX-API-DMAC7.html)
CN (1) CN114729056A (cg-RX-API-DMAC7.html)
AU (1) AU2020303586A1 (cg-RX-API-DMAC7.html)
CA (1) CA3143522A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003435A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000404A2 (cg-RX-API-DMAC7.html)
IL (1) IL289100A (cg-RX-API-DMAC7.html)
MX (1) MX2021015882A (cg-RX-API-DMAC7.html)
WO (1) WO2020264208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976098A4 (en) 2019-05-31 2023-01-18 Zymeworks Inc. METHOD OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT THAT TARGETS HER2 FOR THE TREATMENT OF BILAGE DUCT CANCER
PH12022553407A1 (en) 2020-06-25 2024-04-22 Amunix Pharmaceuticals Inc Her-2 targeted bispecific compositions and methods for making and using the same
CN117616137A (zh) * 2021-05-11 2024-02-27 佳努克斯治疗公司 靶向egfr和cd3的抗体及其用途
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
JP7855148B2 (ja) 2023-02-10 2026-05-07 アムニクス ファーマシューティカルズ, インコーポレイテッド 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
US20240400696A1 (en) 2023-04-17 2024-12-05 Amunix Pharmaceuticals, Inc. Compositions targeting epidermal growth factor receptor and methods for making and using the same
KR20260114559A (ko) 2023-12-08 2026-07-22 아뮤닉스 파마슈티컬스, 인크. 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법
TW202547886A (zh) * 2024-02-02 2025-12-16 美商黛安瑟斯醫療運營公司 用於治療c1s介導的疾病和病症的組成物、劑量和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090252683A1 (en) 2005-10-11 2009-10-08 Micromet Ag Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof
WO2018068652A1 (zh) 2016-10-11 2018-04-19 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
JP2018533909A (ja) 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239180B (zh) * 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
AU2014206217B2 (en) * 2009-02-03 2015-09-17 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
EP2729488A4 (en) * 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
WO2013059524A2 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
EA201691765A1 (ru) * 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
BR112018007703A2 (pt) * 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
IL307684B2 (en) * 2016-09-29 2025-04-01 Amgen Inc Low viscosity antigen binding proteins and methods for preparing them
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090252683A1 (en) 2005-10-11 2009-10-08 Micromet Ag Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof
JP2018533909A (ja) 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
WO2018068652A1 (zh) 2016-10-11 2018-04-19 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Importance of isoelectric point (pI) of antibodies,Antibody Society [online],2017年06月28日,URL: https://www.antibodysociety.org/new-articles/importance-isoelectric-point-pi-antibodies/,[retrieved on 7.22.2024]

Also Published As

Publication number Publication date
JP2022538222A (ja) 2022-09-01
IL289100A (en) 2022-02-01
CO2022000404A2 (es) 2022-05-31
MX2021015882A (es) 2022-04-18
KR20220038356A (ko) 2022-03-28
EP3990499A1 (en) 2022-05-04
CA3143522A1 (en) 2020-12-30
JP2026000901A (ja) 2026-01-06
WO2020264208A1 (en) 2020-12-30
EP3990499A4 (en) 2023-07-05
US20230312729A1 (en) 2023-10-05
CL2021003435A1 (es) 2022-09-02
CN114729056A (zh) 2022-07-08
AU2020303586A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
JP7651481B2 (ja) Cd3抗原結合断片およびそれを含む組成物
US20250163153A1 (en) Release segments and binding compositions comprising same
JP2026000901A (ja) Egfr抗原結合断片およびそれを含む組成物
US12415860B2 (en) Binding moiety for conditional activation of immunoglobulin molecules
JP2024105275A (ja) キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
US20210284728A1 (en) Dual binding moiety
US20240336909A1 (en) Conditional activation of immunoglobulin molecules
JP2026506762A (ja) 薬剤、方法、およびそれらの使用
KR20250166225A (ko) 표피 성장 인자 수용체를 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
RU2851152C1 (ru) Нацеленные на her-2 биспецифические композиции и способы их получения и применения
TW202237667A (zh) 靶向her-2之雙特異性組合物以及其製造及使用方法
BR122026001258A2 (pt) Método de fabricação de um polipeptídeo recombinante e uso de um polipeptídeo recombinante ou de uma composição que compreende o mesmo
BR112018004045B1 (pt) Construto de conjunto de polipeptídeo quimérico e seu uso

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241024

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241101

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260407

R150 Certificate of patent or registration of utility model

Ref document number: 7847433

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150